Lupin is currently trading at Rs. 1461.15, up by 7.80 points or 0.54 % from its previous closing of Rs. 1453.35 on the BSE.
The scrip opened at Rs. 1450.00 and has touched a high and low of Rs. 1465.00 and Rs. 1450.00 respectively. So far 69649 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1874.30 on 14-Mar-2016 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.
Last one week high and low of the scrip stood at Rs. 1476.50 and Rs. 1446.75 respectively. The current market cap of the company is Rs. 65918.32 crore.
The promoters holding in the company stood at 46.71%, while Institutions and Non-Institutions held 41.46% and 11.83% respectively.
Lupin’s Japanese subsidiary, Kyowa Pharmaceutical Industry Co., has entered into an agreement with Astellas Pharma for providing Kyowa the exclusive right to distribute and promote extended-release tablets of quetiapine fumarate in Japan.
Astellas submitted a new drug application (NDA) with the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for the indication of improvement of depressive symptoms associated with bipolar disorder. When Astellas obtains an approval for the new drug application of extended-release tablets of quetiapine fumarate, based on the agreement, Kyowa will exclusively distribute and promote the products in Japan.
Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.